Clinical Trials Details

EA5191 (Lung)

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

Objective

Key eligibility: Non-squamous NSCLC; known molecular alterations in ROS1, RET, MET; at least 1 prior therapy; Stage IV disease/recurrent.

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms